Literature DB >> 19154763

Effective GDNF brain delivery using microspheres--a promising strategy for Parkinson's disease.

E Garbayo1, C N Montero-Menei, E Ansorena, J L Lanciego, M S Aymerich, M J Blanco-Prieto.   

Abstract

Glial cell line-derived neurotrophic factor (GDNF) has shown promise in the treatment of neurodegenerative disorders of basal ganglia origin such us Parkinson's disease (PD). In this study, we investigated the neurorestorative effect of controlled GDNF delivery using biodegradable microspheres in an animal model with partial dopaminergic lesion. Microspheres were loaded with N-glycosylated recombinant GDNF and prepared using the Total Recirculation One-Machine System (TROMS). GDNF-loaded microparticles were unilaterally injected into the rat striatum by stereotaxic surgery two weeks after a unilateral partial 6-OHDA nigrostriatal lesion. Animals were tested for amphetamine-induced rotational asymmetry at different times and were sacrificed two months after microsphere implantation for immunohistochemical analysis. The putative presence of serum IgG antibodies against rat glycosylated GDNF was analyzed for addressing safety issues. The results demonstrated that GDNF-loaded microspheres, improved the rotational behavior induced by amphetamine of the GDNF-treated animals together with an increase in the density of TH positive fibers at the striatal level. The developed GDNF-loaded microparticles proved to be suitable to release biologically active GDNF over up to 5 weeks in vivo. Furthermore, none of the animals developed antibodies against GDNF demonstrating the safety of glycosylated GDNF use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19154763     DOI: 10.1016/j.jconrel.2008.12.010

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  29 in total

1.  Glial Cell Line-Derived Neurotrophic Factor-Transfected Placenta-Derived Versus Bone Marrow-Derived Mesenchymal Cells for Treating Spinal Cord Injury.

Authors:  Yao Lu; Hui Gao; Man Zhang; Bing Chen; Huilin Yang
Journal:  Med Sci Monit       Date:  2017-04-14

2.  Topographical Distribution of Morphological Changes in a Partial Model of Parkinson's Disease--Effects of Nanoencapsulated Neurotrophic Factors Administration.

Authors:  C Requejo; J A Ruiz-Ortega; H Bengoetxea; A Garcia-Blanco; E Herrán; A Aristieta; M Igartua; L Ugedo; J L Pedraz; R M Hernández; J V Lafuente
Journal:  Mol Neurobiol       Date:  2015-06-04       Impact factor: 5.590

Review 3.  The therapeutic potential of IGF-I in skeletal muscle repair.

Authors:  Yao-Hua Song; Jenny L Song; Patrice Delafontaine; Michael P Godard
Journal:  Trends Endocrinol Metab       Date:  2013-04-27       Impact factor: 12.015

4.  Neuroprotective Effects of Antidepressants via Upregulation of Neurotrophic Factors in the MPTP Model of Parkinson's Disease.

Authors:  Sina Shadfar; Yu-Gyeong Kim; Nikita Katila; Sabita Neupane; Uttam Ojha; Sunil Bhurtel; Sunil Srivastav; Gil-Saeng Jeong; Pil-Hoon Park; Jin Tae Hong; Dong-Young Choi
Journal:  Mol Neurobiol       Date:  2016-12-14       Impact factor: 5.590

Review 5.  The role of growth factors as a therapeutic approach to demyelinating disease.

Authors:  Yangyang Huang; Cheryl F Dreyfus
Journal:  Exp Neurol       Date:  2016-03-22       Impact factor: 5.330

6.  Controlled release of glial cell line-derived neurotrophic factor from poly(ε-caprolactone) microspheres.

Authors:  Andrew Agbay; Nima Khadem Mohtaram; Stephanie Michelle Willerth
Journal:  Drug Deliv Transl Res       Date:  2014-04       Impact factor: 4.617

7.  Morphological Changes in a Severe Model of Parkinson's Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors.

Authors:  C Requejo; J A Ruiz-Ortega; H Bengoetxea; A García-Blanco; E Herrán; A Aristieta; M Igartua; J L Pedraz; L Ugedo; R M Hernández; J V Lafuente
Journal:  Mol Neurobiol       Date:  2016-11-14       Impact factor: 5.590

8.  Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson's Disease Model.

Authors:  Brian P Mead; Namho Kim; G Wilson Miller; David Hodges; Panagiotis Mastorakos; Alexander L Klibanov; James W Mandell; Jay Hirsh; Jung Soo Suk; Justin Hanes; Richard J Price
Journal:  Nano Lett       Date:  2017-05-18       Impact factor: 11.189

9.  Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson's Disease.

Authors:  Sara Hernando; Enara Herran; Joana Figueiro-Silva; José Luis Pedraz; Manoli Igartua; Eva Carro; Rosa Maria Hernandez
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

10.  Effect of different sintering methods on bioactivity and release of proteins from PLGA microspheres.

Authors:  Nathan H Dormer; Vineet Gupta; Aaron M Scurto; Cory J Berkland; Michael S Detamore
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2013-06-28       Impact factor: 7.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.